Market Research Logo

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
    • The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
    • The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Chemotherapy Induced Peripheral Neuropathy Overview
    Therapeutics Development
    Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview
    Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis
    Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies
    Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
    Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies
    Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes
    Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
    Achelios Therapeutics, Inc.
    Advinus Therapeutics Ltd
    Amplyx Pharmaceuticals, Inc.
    Can-Fite BioPharma Ltd.
    DermaXon, LLC
    Eisai Co., Ltd.
    Immune Pharmaceuticals Inc.
    INSYS Therapeutics, Inc.
    KPI Therapeutics, Inc.
    Krenitsky Pharmaceuticals Inc.
    Laboratorios Del Dr. Esteve S.A.
    Lpath, Inc.
    MAKScientific, LLC
    Metys Pharmaceuticals AG
    Midatech Pharma US Inc.
    Nemus Bioscience, Inc.
    Neurocentrx Pharma Ltd.
    Panacea Pharmaceuticals, Inc.
    PeriphaGen, Inc.
    PharmatrophiX, Inc.
    PledPharma AB
    Sova Pharmaceuticals, Inc.
    Spectrum Pharmaceuticals, Inc.
    Virobay Inc.
    WEX Pharmaceuticals Inc.
    Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (amitriptyline + ketamine hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-1710 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AXPN-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BR-297 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cannabidiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dimiracetam - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DX-0332 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E-2072 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HM-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ketoprofen - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KP-544 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KRN-5500 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LM11A-31BHS - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Lpathomab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MR-309 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NB-2111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NRX-2922 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NT-24336 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PAN-811 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PGN-503 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    piclidenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pirenzepine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PP-095 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Q-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Pain - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPI-205 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tetrodotoxin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    U-2902 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBY-036 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XT-150 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
    Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
    Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
    Featured News & Press Releases
    Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
    Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
    Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
    Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA
    Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation
    Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016
    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Lpath, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2016
    Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016
    Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report